Immunome Inc (NASDAQ: IMNM) kicked off on Tuesday, down -5.81% from the previous trading day, before settling in for the closing price of $13.26. Over the past 52 weeks, IMNM has traded in a range of $6.93-$30.96.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded 25.65%. With a float of $48.99 million, this company’s outstanding shares have now reached $60.05 million.
Let’s determine the extent of company efficiency that accounts for 55 employees. In terms of profitability, gross margin is 87.4%, operating margin of -2518.49%, and the pretax margin is -2435.02%.
Immunome Inc (IMNM) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Immunome Inc is 18.42%, while institutional ownership is 80.18%. The most recent insider transaction that took place on Sep 19 ’24, was worth 230,224. In this transaction Chief Financial Officer of this company sold 14,380 shares at a rate of $16.01, taking the stock ownership to the 47,476 shares. Before that another transaction happened on Sep 19 ’24, when Company’s Officer proposed sale 14,380 for $16.01, making the entire transaction worth $230,211.
Immunome Inc (IMNM) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 25.65% per share during the next fiscal year.
Immunome Inc (NASDAQ: IMNM) Trading Performance Indicators
Take a look at Immunome Inc’s (IMNM) current performance indicators. Last quarter, stock had a quick ratio of 7.12. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 69.58.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -7.69, a number that is poised to hit -0.55 in the next quarter and is forecasted to reach -2.76 in one year’s time.
Technical Analysis of Immunome Inc (IMNM)
Looking closely at Immunome Inc (NASDAQ: IMNM), its last 5-days average volume was 0.54 million, which is a drop from its year-to-date volume of 0.75 million. As of the previous 9 days, the stock’s Stochastic %D was 66.81%. Additionally, its Average True Range was 0.76.
During the past 100 days, Immunome Inc’s (IMNM) raw stochastic average was set at 24.74%, which indicates a significant decrease from 48.23% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.58% in the past 14 days, which was lower than the 64.69% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.32, while its 200-day Moving Average is $16.29. However, in the short run, Immunome Inc’s stock first resistance to watch stands at $12.92. Second resistance stands at $13.34. The third major resistance level sits at $13.60. If the price goes on to break the first support level at $12.23, it is likely to go to the next support level at $11.97. Now, if the price goes above the second support level, the third support stands at $11.55.
Immunome Inc (NASDAQ: IMNM) Key Stats
The company with the Market Capitalisation of 750.08 million has total of 60,054K Shares Outstanding. Its annual sales at the moment are 14,020 K in contrast with the sum of -106,810 K annual income. Company’s last quarter sales were recorded 2,360 K and last quarter income was -36,120 K.
